It's Not Easy Being Green: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 68: Line 68:


~ Longo et al., 2008 (pancreatic cancer --> targeting cancer)
~ Longo et al., 2008 (pancreatic cancer --> targeting cancer)
~ Aita et al., 2008 (Targeting the VEGF pathway in the treatment of non-small lung cancer cells)
~ Aita et al., 2008 (Targeting the VEGF pathway in the treatment of non-small lung cancer cells)
~ Raskopf et al., 2008 (siRNA targeting VEGF inhibits tumor angiogenesis in vivo)      
 
~ Raskopf et al., 2008 (siRNA targeting VEGF inhibits tumor angiogenesis in vivo)
     
~ Norden et al., 2008 (Novel anti-angiogenic therapies for malignant gliomas)
~ Norden et al., 2008 (Novel anti-angiogenic therapies for malignant gliomas)


Line 77: Line 80:


~ Luo et al., 2008 (short hairpin RNA targeting c-FLIP sensitizes cells to chemotherapy)
~ Luo et al., 2008 (short hairpin RNA targeting c-FLIP sensitizes cells to chemotherapy)
~ Wheate, 2008 (Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils)
~ Wheate, 2008 (Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils)
~ Munnier et al., 2008 (Novel method of doxorubicin–SPION reversible association for magnetic drug targeting)
~ Munnier et al., 2008 (Novel method of doxorubicin–SPION reversible association for magnetic drug targeting)



Revision as of 19:42, 17 November 2008

Follow the Green Team from the T/R lab section through their arduous planning leading up to their final research proposal presentation!

Contributing authors: Daniel Kim, Mimi Yen


Background Information

11/11 Research ideas ~ MY ~

1. Drugs by Air

Although feared by many, the needle is the most common method of drug administration. A new technique developed by a team at MIT uses a stream of gas containing the drug that would be absorbed through the skin. The procedure, known as microscission, uses small inert aluminum oxide crystals to remove the skin’s outer layer and create microconduits through which the medicine can move. Anesthetics are then applied to the region, which offers a less painful alternative to the needle.

Reference: Scientific American http://www.sciam.com/article.cfm?id=new-drug-delivery-techniq

2. Targeted radiation therapy

A team led by the Sloan-Kettering Cancer Center in New York has developed a molecule-sized delivery system that could make radiation therapy for a variety of cancers much safer for patients. Researchers turned to actinium-225, which has a half-life of 10 days, because of its longer half-life than the most often used radioactive element and its capability to generate alpha particles that would kill off nearby tumor cells. Actinium atoms were caged inside rings of carbon and attached to antibodies that specifically recognize cancer cells. This allows the radioactive isotopes to target the cell directly and destroy it from within.

Reference: Scientific American http://www.sciam.com/article.cfm?id=drug-delivers-longer-last

3. Gold Nanoparticles block HIV

TAK-779 was first proposed in 1996 as an effective compound in blocking HIV from hijacking the body’s immune system. The idea was rejected, however, because of the side effects of the drug’s injection and the ineffectiveness of its oral doses. It has long been known that the ammonium salt molecules in TAK-779 triggered the side effects, but no replacement had been found that would be able to bind the drug to the T cells as effectively. Researchers found that attaching 12 modified molecules of TAK-779 to one gold nanoparticle restored the drug’s ability to prevent infection. Since the size of the gold particles are similar to the HIV proteins, it makes the material well suited to block the proteins from coming in contact with key receptors on the T cells.

Reference: Scientific American http://www.sciam.com/article.cfm?id=gold-nanoparticles-hiv

4. A novel insulin delivery system

Chemical engineers at Purdue University reported the successful synthesis of a glucose-sensitive hydrogel that could be used to deliver insulin to diabetic patients. The hydrogel membrane immobilizes glucose oxidase and forms an insulin “reservoir”. In contrast to other hydrogel system that release trapped drugs by swelling, this method works by shrinking the membrane. The trigger for this mechanism is controlled by pH and is accomplished when the body produces high sugar levels. Glucose interacts with the glucose oxidase in the membrane, which yields gluconic acid. This in turns lowers the body’s pH and trigger the gate to open.

Reference: Modern Drug Discovery http://pubs.acs.org/subscribe/journals/mdd/v04/i04/html/MDD04FeatureVogelson.html Dorski, C. M.; Doyle, F. J.; Peppas, N. A. Polym. Mater. Sci. Eng. Proc. 1997, 76, 281.

5. Flu Vaccine Patch

3M Drug Delivery systems has developed a new technology that would deliver its M2e universal flu vaccine using a skin patch instead of the traditional needle injection. Instead, they use microneedle technology that penetrates the skin with minimal discomfort but still allows for the intradermal delivery of therapeutics usually only available through the needle. This also increases the delivery time of the vaccination in the case of the seasonal flu or a pandemic when rapid vaccination of the population is critical to stop the disease from spreading.

Reference: Drug Delivery Technology http://www.drugdeliverytech.com/ME2/dirmod.asp?sid=7326F9BFDFF54B32B7DFFEB6C52F8056&nm=&type=news&mod=News&mid=9A02E3B96F2A415ABC72CB5F516B4C10&tier=3&nid=E78B173082AA4C11AD0BE9D6BE4EEB05

~ DK ~

[Insert Daniel's work]

Conclusion: Both members are particularly interested in the topic of cancer therapy. Continue literature search and decide on Tuesday in class what would be the best direction to take this project.


Literature Search

~ MY ~

Cancer therapies

ANGIOGENESIS INHIBITORS (anti-VEGF agents such as bevacizumab)

Tumor angiogenesis plays a huge role in the progression of cancer. The normal process of angiogensis in the body is controlled by a very tightly regulated system of promoting factors and inhibitors. The "angiogenic switch" may occur during tumor expansion, which may cause some cells to be outside the oxygen diffusion limit and become hypoxic. Tumor cells respond to hypoxia by activing a transcription factor that directly transactivates genes involved in the process of angiogenesis, including the vascular endothelial growht factor (VEGF).

VEGF has been suggested to play a key role in the angiogenesis regulation, as it acts as both an endothelial cell survival factor and as a recruiter of circulating precursors. VEGF overexpression has been significantly correlated with decreased survival in several tumor types. Bevacizumab is a recombinant monoclonal antibody that is humanised by the incorporation of murine BVEGF-binding residues into a human IgG framework. It prevents the interaction between VEGF and its receptors by binding to soluble VEGF.

~ Longo et al., 2008 (pancreatic cancer --> targeting cancer)

~ Aita et al., 2008 (Targeting the VEGF pathway in the treatment of non-small lung cancer cells)

~ Raskopf et al., 2008 (siRNA targeting VEGF inhibits tumor angiogenesis in vivo)

~ Norden et al., 2008 (Novel anti-angiogenic therapies for malignant gliomas)

CHEMOTHERAPY INNOVATIONS

Side effects of chemotherapy are due the drugs taking effect on all of the body's cells. Thus, the main research behind chemotherapy is the search for a method to target cancer cells. By targeting only cancerous cells, patients undergoing chemotherapy would not their health and their lives as significantly affected.

~ Luo et al., 2008 (short hairpin RNA targeting c-FLIP sensitizes cells to chemotherapy)

~ Wheate, 2008 (Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils)

~ Munnier et al., 2008 (Novel method of doxorubicin–SPION reversible association for magnetic drug targeting)

~ DK ~

[Insert Daniel's research]